Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI in Advanced or Metastatic Neuroendocrine Carcinoma
NCT03168607Phase 2Unknown
- Sponsor
- Peking University
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in neuroendocrine carcinoma (NEC), sponsored by Peking University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03168607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168607.